Treatment of COVID 19, WHO recommends the use of two drugs

2 min read


The World Health Organization has recommended two new drugs for the treatment of patients with COVID-19 disease.

The drug baricitinib (a type of drug used to treat rheumatoid arthritis), according to the WHO, is recommended to be used in seriously ill and critical patients, in combination with corticosteroids, which are powerful anti-inflammatory drugs and strengthen the immune response.

Experts have also recommended the use of the synthetic anti-body, Sotrovimab, for people who have non-serious symptoms but are at risk of hospitalization, such as the elderly, those with immunodeficiency and people with chronic diseases such as diabetes.

The WHO said the recommendation is based on data suggesting it improves the chances of survival and reduces the need for patients to be ventilated and has not been found to cause side effects.

WHO experts say baricitinib has similar effects to other arthritis medications, so if these two medications are available, the organization recommends that patients choose one of them. "Based on cost, availability and doctor's recommendation". However, it is not recommended that these two medications be taken at the same time.

The recommendation for the use of these drugs was made from new data from seven studies involving 4,000 patients with COVID-19 with mild, severe, and critical infections.

The drugs recommended today are added to the list of treatments for COVID-19 which includes the use of blocking receptors and systemic corticosteroids for critically ill and critically ill patients. The WHO has also previously recommended the conditional use of monoclonal antibody therapy in certain patients.21Media